$34.70 0.38 (1.08%)
12:02 EDT PFE Stock Quote Delayed 15 Minutes
Previous Close $35.08
Market Cap 202.98B
PE Ratio 9.64
Volume (Avg. Vol.) 7.59M
Day's Range 34.64 - 35.35
52-Week Range 33.97 - 46.47
Dividend & Yield 1.36 (3.92%)
PFE Stock Predictions, Articles, and Pfizer News
- From InvestorPlace
- From the Web
PFE stock recently dropped 20% following the company's latest earnings report. As a result, Pfizer has reached extreme oversold readings that could lead to a pop in the stock.
Seagate, AT&T and Citigroup are just three of the blue-chip dividend stocks that have become cheap stocks to buy recently.
The stock charts of Pfizer, AES and Centurylink have emerged as enticing prospects within a sea of volatility.
Q2 earnings season rolls on and Wall Street tries to not act disappointed by the early end to the latest round of U.S.-China trade talks. Thus, individual stock price action is uneven with all the focus going to a handful of names posting solid results.
Options trading was buzzing in Pfizer, Advanced Micro Devices and Apple on Tuesday. Here are the metrics that matter moving forward.
The stock charts of Southern Co, CF Industries Holdings and National-Oilwell Varco are at inflection points at the midpoint of the week.
The new company emerging from the Pfizer-Mylan deal gets former blockbusters like Lipitor and Celebrex, now generics, and the EpiPen business, which has been an object of scandal.
The stock charts of HBI, TRV and TPR have worked their way into pivotal position as the end of July approaches.
While it was a quiet day for the indices, there were a lot of moves under the surfaces to take note of in the stock market today.
At the close, the Nasdaq Composite slipped 0.44% as the technology sector was one of Monday's laggard groups. That hampered the S&P 500, in which technology is also the largest sector allocation, sending the benchmark U.S. equity gauge lower by 0.16%. The Dow Jones Industrial Average started the week higher by 0.11%.
A new Mylan-Pfizer deal that will have the companies taking part in a merger agreement has MYL stock heading higher on Monday.
By David Moadel
As it prepares to report its second-quarter earnings, Pfizer Stock is set to make some big moves. Now is the time to get in.
In the latest Sangamo Therapeutics news, SGMO stock is gaining after the company's hemophilia A gene therapy study yielded positive results.
The stock charts of CVS Health, Pfizer and Weyerhaeuser head into the midpoint of the week on the verge of major moves.
As we head into the second half of the year, here are three Dow Jones stocks to buy for a long-term portfolio.
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!